GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Core One Labs Inc (XCNQ:COOL) » Definitions » Cyclically Adjusted Price-to-FCF

Core One Labs (XCNQ:COOL) Cyclically Adjusted Price-to-FCF : (As of Apr. 27, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Core One Labs Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Core One Labs Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Core One Labs's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Core One Labs Cyclically Adjusted Price-to-FCF Chart

Core One Labs Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Core One Labs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Core One Labs's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Core One Labs's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Core One Labs's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Core One Labs's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Core One Labs's Cyclically Adjusted Price-to-FCF falls into.



Core One Labs Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Core One Labs's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Core One Labs's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/125.4675*125.4675
=0.000

Current CPI (Dec. 2023) = 125.4675.

Core One Labs Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201309 0.387 97.419 0.498
201312 1.031 96.945 1.334
201403 -0.935 98.604 -1.190
201406 0.182 99.473 0.230
201409 -0.457 99.394 -0.577
201412 -0.238 98.367 -0.304
201503 0.011 99.789 0.014
201506 -4.500 100.500 -5.618
201509 -0.582 100.421 -0.727
201512 -1.826 99.947 -2.292
201603 -0.352 101.054 -0.437
201606 -0.743 102.002 -0.914
201609 -2.388 101.765 -2.944
201612 -3.339 101.449 -4.130
201703 -3.014 102.634 -3.685
201706 -4.949 103.029 -6.027
201709 -6.655 103.345 -8.080
201712 -3.328 103.345 -4.040
201803 -5.486 105.004 -6.555
201806 -4.313 105.557 -5.127
201809 -3.941 105.636 -4.681
201812 -1.465 105.399 -1.744
201903 -1.316 106.979 -1.543
201906 -3.691 107.690 -4.300
201909 -1.287 107.611 -1.501
201912 2.568 107.769 2.990
202003 -0.102 107.927 -0.119
202006 0.178 108.401 0.206
202009 -0.142 108.164 -0.165
202012 -0.121 108.559 -0.140
202103 -0.158 110.298 -0.180
202106 -0.113 111.720 -0.127
202109 -0.071 112.905 -0.079
202112 -0.002 113.774 -0.002
202203 -0.034 117.646 -0.036
202206 -0.010 120.806 -0.010
202209 -0.010 120.648 -0.010
202212 -0.014 120.964 -0.015
202309 0.000 125.230 0.000
202312 0.000 125.468 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Core One Labs  (XCNQ:COOL) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Core One Labs Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Core One Labs's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Core One Labs (XCNQ:COOL) Business Description

Industry
Traded in Other Exchanges
Address
1199 West Hastings Street, Suite 800, Vancouver, BC, CAN, V6E 3T5
Core One Labs Inc is a psychedelic research and development life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. The company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. The Company operates a virtual clinic that assesses patients for the appropriateness of treatment plans for the use of medical cannabis to treat their symptoms. The Company partners with physicians and Health Canada's licensed producers for the provision of treatments, fulfillment of prescriptions, and sale of related products.